Simulations Plus Inc (SLP) - Financial and Strategic SWOT Analysis Review

Simulations Plus Inc (SLP) - Financial and Strategic SWOT Analysis Review


- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Simulations Plus Inc (Simulations Plus) provides advanced software and consulting services to the biopharma industry. The company specializes in accelerating drug discovery, development, and commercialization through innovative, science-based solutions. Its product portfolio includes a range of software products for modeling, simulation, and data analysis, helping clients optimize drug development processes, reduce costs, and enhance regulatory compliance. The company also offers a comprehensive platform covering the entire drug development value chain. It provides adaptive learning solutions and medical communications services to support clinical trial success and post-regulatory commercialization. Simulations Plus is headquartered in Lancaster, California, the US.

Simulations Plus Inc Key Recent Developments

Jan 13,2025: Simulations Plus Supported Development of Every FDA-Approved Drug in 2024
Nov 13,2024: Simulations Plus and the University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting Injectables
Oct 30,2024: Simulations Plus and Partners Awarded New FDA Grant to Validate in Vitro-in Vivo Extrapolation Methods for Complex Formulations
Oct 23,2024: Simulations Plus Announces Q4 and Fiscal 2024 Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note:Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Simulations Plus Inc - Key Facts
Simulations Plus Inc - Key Employees
Simulations Plus Inc - Key Employee Biographies
Simulations Plus Inc - Major Products and Services
Simulations Plus Inc - History
Simulations Plus Inc - Company Statement
Simulations Plus Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Simulations Plus Inc - Business Description
Business Segment: Services
Overview
Performance
Business Segment: Software
Overview
Performance
Geographical Segment: Asia Pacific
Performance
Geographical Segment: EMEA
Performance
Geographical Segment: The US
Performance
R&D Overview
Simulations Plus Inc - Corporate Strategy
Simulations Plus Inc - SWOT Analysis
SWOT Analysis - Overview
Simulations Plus Inc - Strengths
Simulations Plus Inc - Weaknesses
Simulations Plus Inc - Opportunities
Simulations Plus Inc - Threats
Simulations Plus Inc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Simulations Plus Inc, Medical Equipment, Deals By Year, 2019 to YTD 2025
Simulations Plus Inc, Medical Equipment, Deals By Type, 2019 to YTD 2025
Simulations Plus Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Jan 13, 2025: Simulations Plus Supported Development of Every FDA-Approved Drug in 2024
Nov 13, 2024: Simulations Plus and the University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting Injectables
Oct 30, 2024: Simulations Plus and Partners Awarded New FDA Grant to Validate in Vitro-in Vivo Extrapolation Methods for Complex Formulations
Oct 23, 2024: Simulations Plus Announces Q4 and Fiscal 2024 Results
Oct 09, 2024: Simulations Plus Announces Fourth Quarter and Fiscal Year 2024 Earnings and Conference Call Date
Aug 01, 2024: Simulations Plus Releases Dilisym X
Jun 18, 2024: Simulations Plus Announces Third Quarter Fiscal Year 2024 Earnings and Conference Call Date
May 22, 2024: Simulations Plus to Participate in 21st Annual Craig-Hallum Institutional Investor Conference
Apr 04, 2024: U.S. FDA Renews DILIsym Software Licenses for 7th Year
Jan 09, 2024: Simulations Plus Embarks on Collaboration with Northeastern University and The TIM Company Through New FDA Grant
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Simulations Plus Inc, Key Facts
Simulations Plus Inc, Key Employees
Simulations Plus Inc, Key Employee Biographies
Simulations Plus Inc, Major Products and Services
Simulations Plus Inc, History
Simulations Plus Inc, Subsidiaries
Simulations Plus Inc, Key Competitors
Simulations Plus Inc, Ratios based on current share price
Simulations Plus Inc, Annual Ratios
Simulations Plus Inc, Annual Ratios (Cont...1)
Simulations Plus Inc, Annual Ratios (Cont...2)
Simulations Plus Inc, Interim Ratios
Simulations Plus Inc, Medical Equipment, Deals By Year, 2019 to YTD 2025
Simulations Plus Inc, Medical Equipment, Deals By Type, 2019 to YTD 2025
Simulations Plus Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Simulations Plus Inc, Performance Chart (2020 - 2024)
Simulations Plus Inc, Ratio Charts
Simulations Plus Inc, Medical Equipment, Deals By Year, 2019 to YTD 2025
Simulations Plus Inc, Medical Equipment, Deals by Type, 2019 to YTD 2025

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings